{"nctId":"NCT02207725","briefTitle":"A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban","startDateStruct":{"date":"2014-03"},"conditions":["Bleeding"],"count":68,"armGroups":[{"label":"Andexanet","type":"EXPERIMENTAL","interventionNames":["Biological: Andexanet"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Andexanet","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Reasonably healthy men and women aged 50 to 75\n\nExclusion Criteria:\n\n* History of abnormal bleeding, active bleeding or risk factors for bleeding\n* History of thrombosis or risk factors for thrombosis\n* History of adult asthma or use of inhaled medications","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Efficacy: Percent Change From Baseline in Anti-fXa Activity at the Nadir (Parts I and II)","description":"In Part I, the primary endpoint was percent change from baseline in anti-fXa activity at the nadir, when nadir was defined as the smaller value for anti-fXa activity at the +2 minutes or +5 minutes time point following the end of the bolus. In Part II, the primary endpoint was the percent change from baseline in anti-fXa activity from its baseline to nadir, when nadir was defined as the smaller value for anti-fXa activity between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion. The baseline for the primary endpoint in both parts was the anti-fXa activity just prior to administration of andexanet, 3 hours following the Day 4 dose of apixaban. Anti-fXa activity was measured by a modified chromogenic assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.71","spread":"8.559"},{"groupId":"OG001","value":"-93.86","spread":"1.650"},{"groupId":"OG002","value":"-32.70","spread":"5.578"},{"groupId":"OG003","value":"-92.34","spread":"2.809"}]}]}]},{"type":"SECONDARY","title":"Efficacy: Percent Change From Baseline in Anti-fXa Activity at the Nadir (Part II)","description":"The percent change from baseline in anti-fXa activity at the nadir, following the bolus, when nadir was defined as the smaller value for anti-fXa activity at the +2 minute or +5 minute time point after the completion of the andexanet bolus (Part II). Baseline was the last assessment obtained prior to the first dose of andexanet or placebo","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.73","spread":"4.104"},{"groupId":"OG001","value":"-93.49","spread":"1.525"}]}]}]},{"type":"SECONDARY","title":"Efficacy: Number of Participants With ≥80% Reduction in the Anti-fXa Activity From Baseline to Nadir","description":"Occurrence of ≥80% reduction in anti-fXa activity from its baseline to nadir, when nadir was defined as the smaller value for anti-fXa activity at the +2 minute or +5 minute time point after the completion of the andexanet bolus (Part I) or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \\[Part II\\]. Baseline was the last assessment obtained prior to the first dose of andexanet or placebo","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy -Change From Baseline in Free Apixaban Concentration at the Nadir","description":"Change from baseline in free apixaban concentration (ng/mL) at the nadir, when nadir was defined as the smaller value for free apixaban at the +2 minute or +5 minute time point after the completion of the andexanet bolus (Part I) or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \\[Part II\\]. Free plasma concentrations of apixaban was determined using a validated method that involved analysis of citrated human plasma with high-throughput equilibrium dialysis followed by liquid chromatography mass spectrometry.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.854","spread":"1.6152"},{"groupId":"OG001","value":"-9.338","spread":"3.2043"},{"groupId":"OG002","value":"-2.964","spread":"1.1567"},{"groupId":"OG003","value":"-6.480","spread":"2.7814"}]}]}]},{"type":"SECONDARY","title":"Efficacy: Change in Thrombin Generation (ETP) From Baseline to Its Peak [Parts I and II]","description":"Change in ETP from baseline to its peak, where peak was defined as the largest value for ETP between the +2 minute time point and the +10 minute time point after the end of the andexanet bolus (inclusive) {Part I\\] or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \\[Part II\\]. Baseline was the last assessment obtained prior to the first dose of andexanet or placebo. ETP was measured using a tissue factor-initiated thrombin generation assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.182","spread":"125.7621"},{"groupId":"OG001","value":"1323.180","spread":"335.4321"},{"groupId":"OG002","value":"189.409","spread":"184.7842"},{"groupId":"OG003","value":"1193.060","spread":"263.3471"}]}]}]},{"type":"SECONDARY","title":"Efficacy: Number of Participants With Thrombin Generation (ETP) Above the Lower Limit of the Derived Normal Range at Its Peak (mITT Population)","description":"Number of participants with ETP above the lower limit of the normal range at its peak, between the +2 minute time point and the +10 minute time point after the end of the andexanet bolus (inclusive) \\[Part I\\] or between the 110-minute time point (10 minutes prior to the end of the continuous infusion) and the 5-minute time point after the end of the continuous infusion (inclusive) \\[Part II\\]. ETP was measured using a tissue factor-initiated thrombin generation assay","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"23","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":["Infusion Related Reaction","Vessel Puncture Site Haemorrhage","Dermatitis Contact","Headache","Vessel Puncture Site Pain"]}}}